trial
as of 2026-07-01Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
NCTId NCT03513549
at a glance
Phase — · Suspended
Enrollment 10,000 (estimated)
Sponsored by Alexza Pharmaceuticals, Inc.
Primary completion 2027-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Suspended
Enrollment
10,000 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2014-11-04
Primary completion
2027-02
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Alexza Pharmaceuticals, Inc.Lead Sponsor
Pharmaceutical Research AssociatesCollaborator
Sites
1 total
Raleigh, United States
Facts & assertions
4 sourced
Enrollment
10,000
Phase
NA
Primary Completion Date
2027-02
Status
SUSPENDED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication